Skip to main content

Table 1 Baseline characteristics

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Age (in years, at date of registration)

Mean

30.5

 Std

15.38

 Min

18

 Max

70

Gender

 

 Male

N=10, 83%

 Female

N=2, 17%

Institution

 

 DFCI

N=4, 33.3%

 MGH

N=8, 66.7%

Performance status

 

 0

N=6, 50%

 1

N=6, 50%

Prior surgery

 

 Yes

N=9, 75%

 No

N=3, 25%

Prior radiation

 Yes

N=9, 75%

 No

N=3, 25%

Number of prior radiation treatments

 N (patients)

9

 Mean (#prior treatments)

1.7

 Std

1.1

 Median

1.0

 Min

1

 Max

4

Prior Chemotherapy

 

 Yes

N=12, 100%

Number of prior chemotherapy treatments

 

 N (patients)

12

 Mean (#prior treatments)

6.5

 Std

6.4

 Median

5

 Min

1

 Max

20